Biomarkers of atherosclerosis: Clinical applications

Current Cardiology Reports

Volumn 10, Issue 6, 2008, Pages 497-504

  Brown, Todd M ^a   Bittner, Vera ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALDOSTERONE; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CHYLOMICRON; CREATININE; CYSTATIN C; FIBRINOGEN; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 6; INTERMEDIATE DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MYELOPEROXIDASE; PHOSPHOLIPASE A2; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; RENIN; ROSUVASTATIN; TRANDOLAPRIL; TROPONIN I; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VERY LOW DENSITY LIPOPROTEIN;

ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIAGNOSTIC VALUE; DISEASE MARKER; ELECTROCARDIOGRAM; HEART INFARCTION; HUMAN; INFLAMMATION; PREDICTION; PROGNOSIS; PROTEIN SYNTHESIS; RISK ASSESSMENT; RISK FACTOR; ROC CURVE;

ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CYSTATIN C; HUMANS; INFLAMMATION; LIPOPROTEINS; MODELS, THEORETICAL; NATRIURETIC PEPTIDE, BRAIN; RISK FACTORS; TIME FACTORS; TROPONIN;

EID: 58249142025     PISSN: 15233782     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11886-008-0078-1     Document Type: Article

References (50)

1. Wilson PW, D'Agostino RB, Levy D, et al.: Prediction of coronary heart disease using risk factor categories. Circulation 1998, 97: 1837-1847.
2. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [no authors listed]. JAMA 2001, 285: 2486-2497.
3. Lloyd-Jones DM, Leip EP, Larson MG, et al.: Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation 2006, 113: 791-798.
4. Ware JH: The limitations of risk factors as prognostic tools. N Engl J Med 2006, 355: 2615-2617.
5. Cook NR: Use and misuse of the receiver operator characteristic curve in risk prediction. Circulation 2007, 115: 928-935.
6. Brunzell JD, Davidson M, Furberg CD, et al.: Lipoprotein management in patients with cardiometabolic risk: Consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol 2008, 51: 1512-1524.
7. Sacks FM: The apolipoprotein story. Atheroscler Suppl 2006, 7: 23-727.
8. Barter PJ, Ballantyne CM, Carmena R, et al.: Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: Report of the thirty person/ten country panel. J Intern Med 2006, 259: 247-258.
9. Frontini MG, Srinivasan SR, Xu J, et al.: Usefulness of childhood non high density lipoprotein cholesterol levels versus other lipoprotein measures in predicting adult subclinical atherosclerosis: The Bogalusa Heart Study. Pediatrics 2008, 121: 924-929.
10. Ingelsson E, Schaefer EJ, Contois JH, et al.: Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA 2007, 298: 776-785.
11. van der Steeg WA, Boekholdt SM, Stein EA, et al.: Role of the apolipoprotein B-apolipoprotein A-1 ratio in cardiovascular risk assessment: A case-control analysis in EPIC-Norfolk. Ann Intern Med 2007, 146: 640-648.
12. Virani SS, Polsani VR, Nambi V: Novel markers of inflammation in atherosclerosis. Curr Atheroscler Rep 2008, 10: 164-170.
13. Nambi V: The use of myeloperoxidase as a risk marker for atherosclerosis. Curr Atheroscler Rep 2005, 7: 127-131.
14. Meuwese MC, Stroes ES, Hazen SL, et al.: Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: The EPIC-Norfolk Prospective Population study. J Am Coll Cardiol 2007, 50: 159-165.
15. Garza CA, Montori VM, McConnell JP, et al.: Association between lipoprotein-associated phospholipase A2 and cardiovascular disease: A systematic review. Mayo Clin Proc 2007, 82: 159-165.
16. Ballantyne CM, Hoogeveen RC, Bang H, et al.: Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Arch Intern Med 2005, 165: 2479-2484.
17. Ridker PM: C-reactive protein and the prediction of cardiovascular events among those at intermediate risk. J Am Coll Cardiol 2007, 49: 2129-2138.
18. Sabatine MS, Morrow DA, Jablonski KA, et al.: Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease. Circulation 2007, 115: 1528-1536.
19. Pearson TA, Mensah GA, Alexander RW, et al.: Markers of inflammation and cardiovascular disease: Application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003, 107: 499-511.
20. Vidula H, Tian L, Liu K, et al.: Biomarkers of inflammation and thrombosis as predictors of near-term mortality in patients with peripheral arterial disease: A cohort study. Ann Intern Med 2008, 148: 85-93.
21. Cook NR, Buring JE, Ridker PM: The effect of including C-reactive protein in cardiovascular risk prediction models for women. Ann Intern Med 2006, 145: 21-29.
22. Ridker PM, Buring JE, Rifai N, Cook NR: Development and validation of improved algorithms for the assessment of global cardiovascular risk in women. JAMA 2007, 297: 611-619.
23. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: An individual participant meta-analysis. Fibrinogen Studies Collaboration [no authors listed]. JAMA 2005, 294: 1799-1809.
24. Jenny NS, Yanez ND, Psaty BM, et al.: Inflammation biomarkers and near-term death in older men. Am J Epidemiol 2007, 165: 684-695.
25. Zakai NA, Katz R, Jenny NS, et al.: Inflammation and hemostasis biomarkers and cardiovascular risk in the elderly: The Cardiovascular Health Study. J Thromb Haemost 2007, 5: 1128-1135.
26. Thygesen K, Alpert JS, White HD; Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction: Universal definition of myocardial infarction. J Am Coll Cardiol 2007, 50: 2173-2195.
27. Antman EM, Anbe DT, Armstrong PW, et al.: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). 2004. Available at http://www.acc.org/qualityandscience/clinical/guidelines/ stemi/STEMI%20Full%20Text.pdf. Accessed August 15, 2008.
28. Anderson JL, Adams CD, Antman EM, et al.: ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: A report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction): Developed in collaboration with the American College of Emergency Physicians, American College of Physicians, Society for Academic Emergency Medicine, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2007, 50: E1-e157.
29. Schulz O, Paul-Walter C, Lehmann M, et al.: Usefulness of detectable levels of troponin, below the 99th percentile of the normal range, as a clue to the presence of underlying coronary artery disease. Am J Cardiol 2007, 100: 764-769.
30. Agewall S, Olsson T, Lowbeer C: Usefulness of troponin levels below the diagnostic cut-off level for acute myocardial infarction predicting prognosis in unselected patients admitted to the coronary care unit. Am J Cardiol 2007, 99: 1357-1359.
31. Zethelius B, Johnston N, Venge P: Troponin I as a predictor of coronary heart disease and mortality in 70-year old men: A community-based cohort. Circulation 2006, 113: 1071-1078.
32. de Lemos JA, McGuire DK, Drazner MH: B-type natriuretic peptide in cardiovascular disease. Lancet 2003, 362: 316-322.
33. Omland T, de Lemos JA: Amino-terminal pro-B-type natriuretic peptides in stable and unstable ischemic heart disease. Am J Cardiol 2008, 101(Suppl): 61A-66A.
34. Khan SQ, Quinn P, Davies JE, Ng LL: N-terminal pro-Btype natriuretic peptide is better than TIMI risk score at predicting death after acute myocardial infarction. Heart 2008, 94: 40-43.
35. Weber M, Bazzino O, Navarro Estrada JL, et al.: Nterminal B-type natriuretic peptide assessment provides incremental prognostic information in patients with acute coronary syndromes and normal troponin T values upon admission. J Am Coll Cardiol 2008, 51: 1188-1195.
36. Windhausen F, Hirsch A, Sanders GT, et al.: N-terminal pro-brain natriuretic peptide for additional risk stratification in patients with non-ST-elevation acute coronary syndrome and an elevated troponin T: An Invasive versus Conservative Treatment in Unstable coronary Syndromes (ICTUS) substudy. Am Heart J 2007, 153: 485-492.
37. Bibbins-Domingo K, Gupta R, Na B, et al.: N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular events, and mortality in patients with stable coronary heart disease. JAMA 2007, 297: 169-176.
38. Omland T, Sabatine MS, Jablonski KA, et al.: Prognostic value of B-type natriuretic peptides in patients with stable coronary artery disease. J Am Coll Cardiol 2007, 50: 205-214.
39. N-terminal pro-B-type natriuretic peptide, vascular disease risk, and cholesterol reduction among 20,536 patients in the MRC/BHF Heart Protection Study. Heart Protection Study Collaborative Group [no authors listed]. J Am Coll Cardiol 2007, 49: 311-319.
40. Olsen MH, Hansen TW, Christensen MK, et al.: N-terminal pro-brain natriuretic peptide, but not high sensitivity C-reactive protein, improves cardiovascular risk prediction in the general population. Eur Heart J 2007, 28: 1374-1381.
41. Ix JH, Shlipak MG, Chertow GM, Whooley MA: Association of cystatin C with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease: Data from the Heart and Soul study. Circulation 2007, 115: 173-179.
42. Maahs DM, Ogden LG, Kretowski A, et al.: Serum cystatin C predicts progression of subclinical coronary atherosclerosis in individuals with type 1 diabetes. Diabetes 2007, 56: 2774-2779.
43. Blankenberg S, McQueen MJ, Smieja M, et al.: Comparative impact of multiple biomarkers and N-terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) study. Circulation 2006, 114: 201-208.
44. Wang TJ, Gona P, Larson MG, et al.: Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 2006, 355: 2631-2639.
45. Shlipak MG, Ix JH, Bibbins-Domingo K, et al.: Biomarkers to predict recurrent cardiovascular disease: The Heart and Soul study. Am J Med 2008, 121: 50-57.
46. Zethelius B, Berglund L, Sundstrom J, et al.: Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med 2008, 358: 2107-2116.
47. de Lemos JA, Lloyd-Jones DM: Multiple biomarker panels for cardiovascular risk assessment. N Engl J Med 2008, 358: 2172-2174.
48. Ridker PM; JUPITER Study Group: Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: Rationale and design of the JUPITER trial. Circulation 2003, 108: 2292-2297.
49. Ridker PM, Fonseca FA, Genest J, et al.: Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein. Am J Cardiol 2007, 100: 1659-1664.
50. JUPITER halted: Rosuvastatin significantly reduces cardiovascular morbidity and mortality. Available at http://www.theheart.org/article/ 852735.do. Accessed August 15, 2008.